Drugs / PF-04895162
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01691274 | Oct 2012 → Mar 2013 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04895162 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01691274 ↗ |
| Known as | ICA-105665 | “This study illustrates how DILIsym, a computational representation of liver injury, was able to reproduce species differences in liver toxicity due to PF-04895162 (ICA-105665).” PMID 31624633 ↗ Oct 2019 |
| Action | Inhibit | “BSEP inhibition by PF-04895162” PMID 31624633 ↗ Oct 2019 |
| Route | Oral | “multiple oral doses” NCT01691274 ↗ |